Francis M. Senecal

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

David J. Kuter, James B. Bussel, Roger M. Lyons et al. · The Lancet · 2008 · 862 citations

Medicine, Hematology, Pharmacology +6

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer

Harry D. Bear, Gong Tang, Priya Rastogi et al. · New England Journal of Medicine · 2012 · 469 citations · Full text

Medicine, Oncology, Pharmacology +13

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

Arlene Chan, Beverly Moy, Janine Mansi et al. · Clinical Breast Cancer · 2020 · 215 citations · Full text

Medicine, Oncology, Pharmacology +17